Saturday, April 06, 2024 7:33:18 PM
By my count we're at day T-45 based on 150 days, but the whole process could be shortened by 30 or more days, we could have approval any time in the next two weeks. The basher's are throwing anything against the wall they can fine, but nothing is sticking.
Of course even with UK approval they won't stop. The issues will change to the EDEN not being qualified, and the FDA never being willing to do what the UK has done. In short the bashers will bash until those who're paying them realize it's not working, or move to the long side themselves.
By this time next month we could be a very different stock, we very well might even be at a share price where we can apply with a major exchange once all requirements have been met. It's even possible that we could have new partners or contractors working to initiate new trials, etc. I don't know that it can all come together that fast, but I think it's possible if these things have been set in motion many months ago, but waiting for just one thing, the initial approval of the vaccine.
Gary
Of course even with UK approval they won't stop. The issues will change to the EDEN not being qualified, and the FDA never being willing to do what the UK has done. In short the bashers will bash until those who're paying them realize it's not working, or move to the long side themselves.
By this time next month we could be a very different stock, we very well might even be at a share price where we can apply with a major exchange once all requirements have been met. It's even possible that we could have new partners or contractors working to initiate new trials, etc. I don't know that it can all come together that fast, but I think it's possible if these things have been set in motion many months ago, but waiting for just one thing, the initial approval of the vaccine.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
